Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29898808 | 1.00 | KMT2A (0.54) | KMT2AMEN1CES2CES1GAA | |
| SCHEMBL4026691 | 0.87 | CES2 (0.55) | KMT2AMEN1CES2CES1GAA | |
| SCHEMBL1585165 | 0.84 | CYP11B1 (0.48) | KMT2AMEN1CES2CES1ALDH1A1 | |
| SCHEMBL21401288 | 0.84 | ESR1 (0.55) | KMT2AMEN1CES2CES1GAA | |
| SCHEMBL14916617 | 0.83 | CES2 (0.42) | KMT2AMEN1CES2CES1GAA | |
| SCHEMBL13209693 | 0.83 | CES2 (0.42) | KMT2AMEN1CES2CES1GAA | |
| SCHEMBL1534517 | 0.83 | CES2 (0.42) | KMT2AMEN1CES2CES1ALDH1A1 | |
| SCHEMBL2100806 | 0.83 | CES2 (0.42) | KMT2AMEN1CES2CES1GAA | |
| SCHEMBL10781644 | 0.81 | KMT2A (0.50) | KMT2AMEN1CES2CES1GAA | |
| SCHEMBL18284519 | 0.80 | KMT2A (0.40) | KMT2AMEN1CES2CES1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115869924-B | Defect type zirconium-based metal organic framework adsorbent and preparation method thereof | 华南理工大学 | 2024-08-13 | — | — | CN | claimed |
| CN-115869924-A | Defective zirconium-based metal organic framework adsorbent and preparation method thereof | 华南理工大学 | 2023-03-31 | — | — | CN | claimed |
| CN-115869924-B | Defect type zirconium-based metal organic framework adsorbent and preparation method thereof | 华南理工大学 | 2024-08-13 | — | — | CN | disclosed |
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2024-06-13 | — | — | US | disclosed |
| EP-4301745-A1 | PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS | King's College London (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| CN-115869924-A | Defective zirconium-based metal organic framework adsorbent and preparation method thereof | 华南理工大学 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022185055-A1 | PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2022-09-09 | — | — | WO | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
| EP-0898566-B1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL NV (NL) | 2002-11-06 | — | — | EP | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| US-5494918-A | ANTICHOLESTEROL AGENTS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5385912-A | Hypocholesterolemic or hypolipidemic agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1992015579-A1 | MULTICYCLIC TERTIARY AMINE POLYAROMATIC SQUALENE SYNTHETASE INHIBITORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | KMT2A 2475/4885MEN1 4873/4885CES2 467/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | KMT2A 2418/4885MEN1 2749/4885CES2 4807/4885 |
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | HCN2, HCN1, HCN3 | KMT2A 3966/4885MEN1 3809/4885CES2 2511/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | KMT2A 2557/4885MEN1 2449/4885CES2 3444/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | KMT2A 1807/4885MEN1 3408/4885CES2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.